A novel human epidermal growth factor receptor-3 targeting antibody-drug conjugate for treatment of cancer
An Italian SME specialized in drug discovery has developed and patented a novel human epidermal growth factor receptor-3 (HER-3) targeting antibody-drug conjugate (ADC) for treating cancer. This molecule has shown potent therapeutic efficacy combined with a good safety profile. The company is looking for pharmaceutical companies or investors for financial or license agreement to further develop the product in clinical trials. A research cooperation agreement is also foreseen.